In salvage effort, Sellas cherry picks some positive mid-stage cancer vaccine data
Eight months after Sellas $SLS reverse merged its way onto Nasdaq through what was left of Galena following the pivotal implosion of NeuVax, the microcap …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
